99764-63-3

Basic information

• Product Name: H-LEU-SER-P-NITRO-PHE-NLE-ALA-LEU-OME TFA
• Synonyms: LSF(NO2)-NLE-AL-METHYL ESTER;H-LEU-SER-PHE(4-NO2)-NLE-ALA-LEU-OME TFA;H-LEU-SER-P-NITRO-PHE-NLE-ALA-LEU-OME TFA;LEU-SER-PHE(NO2)-NLE-ALA-LEU-OME;LEU-SER-P-NITRO-PHE-NLE-ALA-LEU-METHYL ESTER TFA;LEUCINE-SERINE-P-NITRO-PHENYLALANINE-NLE-ALANINE-LEUCINE METHYL ESTER;Leu-Ser-p-nitro-Phe-Nle-Ala-Leu methyl ester;H-Leu-Ser-p-nitro-Phe-Nle-Ala-Leu-OMe
• CAS NO: 99764-63-3
• Molecular Formula: C₂HF₃O₂*C₃₄H₅₅N₇O₁₀
• Molecular Weight: 835.86
• Mol File: 99764-63-3.mol
• Article Data: 156

Chemical Properties

• Appearance: /
• Storage Temp.: -15°C
• CAS DataBase Reference: H-LEU-SER-P-NITRO-PHE-NLE-ALA-LEU-OME TFA(CAS DataBase Reference)
• NIST Chemistry Reference: H-LEU-SER-P-NITRO-PHE-NLE-ALA-LEU-OME TFA(99764-63-3)
• EPA Substance Registry System: H-LEU-SER-P-NITRO-PHE-NLE-ALA-LEU-OME TFA(99764-63-3)

Safety Data

• Hazardous Substances Data: 99764-63-3(Hazardous Substances Data)

Upstream product

• 123-75-1 pyrrolidine 
• 442688-36-0 1-[N-(Tert-butoxycarbonyl)piperidin-4yl]-3-(3-chloropropyl)-1,3-dihydrobenzimidazol-2-one 
• 7688-25-7 1,4-di(diphenylphosphino)-butane 
• 75-36-5 acetyl chloride 
• 7732-18-5 water 
• 38184-47-3 3,5-dimethyl-1-pyrazolylformaminidium nitrate 
• 75-05-8 acetonitrile 
• 3647-69-6 4-(2-chloroethyl)morpholine hydrochride 
• 221284-81-7 1-(1-(2-(2,2,2-trifluoroethoxy)-4-hydroxyphenylacetyl)piperidin-4-yl)-4H-3,1-benzoxazin-2(1H)-one 
• 109-01-3 1-methyl-piperazine 
• 162046-54-0 4-((5-benzimidazolylcarbonyl)amino)phenylacetic acid 
• 35386-24-4 1-(2-Methoxyphenyl)piperazine 
• 39512-50-0 N-(o-Chlorophenyl)piperazine 

Downstream Products

• 548770-22-5 methyl-phenyl-carbamic acid 4-{2-[(pyridine-3-carbonyl)-amino]-ethyl}-phenyl ester 
• 224445-42-5 [(4-{(S)-2-Acetylamino-2-[(S)-1-(3-carbamoyl-4-cyclohexylmethoxy-phenyl)-ethylcarbamoyl]-ethyl}-phenyl)-(diethoxy-phosphoryl)-methyl]-phosphonic Acid Diethyl Ester 
• 333995-98-5 1-Acetyl-N-(3-chlorophenyl)-N-[3-[4-(2-benzthiazolylthio)-1-piperidinyl]propyl]-4-piperidinecarboxamide Hydrochloride 
• 223490-48-0 (3-{[(4-Pyrazol-1-yl-benzyl)-(thiazole-2-sulfonyl)-amino]-methyl}-phenoxy)-acetic acid hydrochloride salt 
• 202819-52-1 (RS)-3-amino-2-oxo-1-benzyl-azepine 
• 477583-12-3 N-[1-(2,5-dioxo-4-imidazolidinyl)cyclopentyl]-4-[(2-methyl-4-quinolinyl)methoxy]benzamide 
• 503169-69-5 methyl (3S,4S)-4-({4-[(2-methyl-4-quinolinyl)methyl]benzoyl}amino)-1-(2-propynyl)-3-pyrrolidinecarboxylate 
• 548770-29-2 methyl-phenyl-carbamic acid 2-[4-(2-pyrrolidin-1-yl-ethoxy)-benzenesulfonyl]-1,2,3,4-tetrahydro-isoquinolin-7-yl ester 
• 548770-51-0 methyl-phenyl-carbamic acid 4-[2-(4,4-dimethyl-2,6-dioxo-piperidin-1-yl)-ethyl]-phenyl ester 
• 548770-38-3 3,3-Dimethyl-4-{2-[4-(methyl-phenyl-carbamoyloxy)-phenyl]-ethylcarbamoyl}-butyric acid 
• 548770-23-6 methyl-phenyl-carbamic acid 4-[2-(2-dimethylamino-acetylamino)-ethyl]-phenyl ester 
• 777054-54-3 methyl-phenyl-carbamic acid 4-{2-[4-(4-methyl-piperazin-1-ylmethyl)-benzoylamino]-ethyl}-phenyl ester 
• 548770-31-6 methyl-phenyl-carbamic acid 4-{2-[(1-methyl-piperidine-4-carbonyl)-amino]-ethyl}-phenyl ester 

Relevant articles and documents

TEMPLATES FOR NUCLEATION AND PROPAGATION OF PEPTIDE SECONDARY STRUCTURE

Compounds having the Formula I and pharmaceutically acceptable salts thereof are provided in which the variables are described herein. Methods of making the compounds of Formula I are also disclosed.

Spirocyclic nitriles as protease inhibitors

The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.

Substituted Aminothiazole Prodrugs of Compounds with Anti-HCV Activity

The invention provides amino-substituted aminothiazole compounds of Formula I and Formula II where A is a group of the formula: and the variables X, Y, R, and R1 to R7 are described herein. These compounds are prodrugs of compounds useful as inhibitors of viral replication. Compositions containing such compounds, and methods of treating viral infections with these compounds, as well as to processes and intermediates useful for preparing such compounds are also provided by the invention.